Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

nical and clinical trial. 

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc., an Amgen subsidiary, is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com.

Onyx Pharmaceuticals is on Twitter. Sign up to follow our Twitter feed @OnyxPharm at http://twitter.com/OnyxPharm.

Amgen Forward Looking Statements
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described.
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... May 15, 2012, JoVE ( Journal of Visualized ... United States government,s Defense Threat Reduction Agency (DTRA). ... University,s Dr. Chris Schafmeister and State University of New York ... The support of scientists conducting research for DTRA has significant ...
... Reportlinker.com announces that a new ... its catalogue: , Neuroendocrine Carcinoma ... Forecast to 2019 ... Therapeutics - Pipeline Assessment and Market ...
... BGI, one of the world,s largest genomics organizations, ... been successfully installed at its facility in Shenzhen, China. The ... sequencing technologies and enhance BGI,s long read sequencing capability. ... a Roche Company, features the unique combination of long reads, ...
Cached Biology Technology:JoVE partners with US government to publish cutting-edge defense research 2Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 2Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 3Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 4Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 5Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 6Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 7Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 8Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 9Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 10BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research 2BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research 3
(Date:4/24/2014)... turtle is the largest river turtle in North America, ... almost a century. Now researchers from Florida and the ... one species but three. , Examining museum specimens ... in this ancient reptile. , Once heavily hunted for ... of Campbell,s Turtle Soup in the 1960s the ...
(Date:4/23/2014)... prevalence of asthma, allergies and other chronic inflammatory disorders ... in part to their reduced exposure to the microbes ... scientific paper. , The article, published in the journal ... living in urban centers who have less access to ... inflammation, a condition caused by immune system dysfunction. , ...
(Date:4/23/2014)... most in their mid-thirties and forties, face a ... within two decades. "Mutant" protein clusters, long blamed ... been the primary focus of therapies in development ... from Prof. Gerardo Lederkremer and Dr. Julia Leitman ... and Immunology, in collaboration with Prof. Ulrich Hartl ...
Breaking Biology News(10 mins):Two new US turtle species described 2Two new US turtle species described 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3On the defensive 2On the defensive 3
... A new study from researchers at Queen Mary, University of ... in self-managing their disease. People with diabetes have to ... their condition. This includes not only monitoring the level of ... restrictive diet but also social challenges such as negotiating relatives, ...
... N.Y. -- It turns out that the milk of human ... Research by psychologists at the University at Buffalo and ... part of the reason some people are kind and generous ... Poulin, PhD, assistant professor of psychology at UB, is the ...
... of the woodpecker,s resistance to head impact injury are ... group from the Key Laboratory for Biomechanics and Mechanobiology ... and Medical Engineering, Beihang University, and the School of ... out to study this problem. After 3 years of ...
Cached Biology News:Approach to diabetes self-management too narrow, study suggests 2Approach to diabetes self-management too narrow, study suggests 3Study finds peoples' niceness may reside in their genes 2Mechanical properties and microstructure of cranial and beak bones of the woodpecker and the lark 2
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
...
...
...
Biology Products: